Zobrazeno 1 - 10
of 14
pro vyhledávání: '"E. Jay Bienen"'
Autor:
G. Makinson, E Jay Bienen, Margaret Noyes Essex, Jack Mardekian, Markay Hopps, Margarita Udall
Publikováno v:
JCR: Journal of Clinical Rheumatology. 23:160-166
OBJECTIVES The aim of this study was to evaluate relationships between serum uric acid (SUA) and newly emergent acute myocardial infarction (AMI), congestive heart failure (CHF), coronary artery disease (CAD), composite cardiovascular (CV) events (AM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b3644f1457325fe3e142a87b6c7180f
https://doi.org/10.1097/rhu.0000000000000496
https://doi.org/10.1097/rhu.0000000000000496
Publikováno v:
Patient Preference and Adherence.
David L Gandell,1 E Jay Bienen,2 Jennifer Gudeman3 1Department of Obstetrics and Gynecology, University of Rochester, Rochester, NY, USA; 2The Curry Rockefeller Group, Tarrytown, NY, USA; 3Medical Affairs, AMAG Pharmaceuticals Inc., Waltham, MA, USA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3808b16c4f3d55fc56d5aa056c298970
https://www.dovepress.com/mode-of-injection-and-treatment-adherence-results-of-a-survey-characte-peer-reviewed-article-PPA
https://www.dovepress.com/mode-of-injection-and-treatment-adherence-results-of-a-survey-characte-peer-reviewed-article-PPA
Publikováno v:
Quality of Life Research. 26:467-477
To map relationships between painDETECT, a neuropathic pain (NeP) screening tool, and EQ-5D-3L health status in a real-world setting. Patients with physician-confirmed NeP and painDETECT score classifications of nociceptive (n = 79), transitional (n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5e553fa04444235703528c61ddf4ecc
https://doi.org/10.1007/s11136-016-1379-2
https://doi.org/10.1007/s11136-016-1379-2
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Alesia Sadosky,1 Vijaya Koduru,2 E Jay Bienen,3 Joseph C Cappelleri4 1Pfizer Inc, New York, NY, 2Eliassen Group, New London, CT, 3Outcomes Research Consultant, New York, NY, 4Pfizer Inc, Groton, CT, USA Background: painDETECT is a screening measure f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::083664ea3a79f8dfc5df5889761122ca
https://doi.org/10.2147/ceor.s105402
https://doi.org/10.2147/ceor.s105402
Publikováno v:
Patient Related Outcome Measures
Joseph C Cappelleri,1 Vijaya Koduru,2 E Jay Bienen,3 Alesia Sadosky4 1Pfizer Inc, Groton, CT, USA; 2Eliassen Group, New London, CT, USA; 3Outcomes Research Consultant, New York, NY, USA; 4Pfizer Inc, NewYork, NY, USA Purpose: To psychometrically eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71af704977edd32e1cf6631d41abf20a
https://doi.org/10.2147/prom.s101892
https://doi.org/10.2147/prom.s101892
Autor:
Jack Mardekian, Alesia Sadosky, Sarah Dubrava, Bruce Parsons, E Jay Bienen, John D. Markman, Markay Hopps
Publikováno v:
Pain Medicine. 18:107-115
Objective. To identify variables correlated with a diagnosis of diabetic peripheral neuropathy (DPN) using random forest modeling applied to electronic health records. Design. Retrospective analysis. Setting. Humedica de-identified electronic health
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0746a19ae55a8c6565099c2be03af4a
https://doi.org/10.1093/pm/pnw096
https://doi.org/10.1093/pm/pnw096
Publikováno v:
Journal of Pain Research
Joseph C Cappelleri,1 Vijaya Koduru,2 E Jay Bienen,3 Alesia Sadosky41Pfizer Inc, Groton, CT, USA; 2Eliassen Group, New London, CT, USA; 3Outcomes Research Consultant, New York, NY, USA; 4Pfizer Inc, New York, NY, USABackground: Similarities and diffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35e18dc8ee933ecd5b18d97a32378020
http://europepmc.org/articles/PMC4403687
http://europepmc.org/articles/PMC4403687
Publikováno v:
Clinical Therapeutics. 34:1056-1069
Dalfampridine (fampridine outside the United States) is a broad-spectrum potassium channel blocker. Dalfampridine extended-release tablets have been approved by the US Food and Drug Administration to improve walking in patients with multiple sclerosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf45fe3397fa445b9a5ba66c41b07850
https://doi.org/10.1016/j.clinthera.2012.03.007
https://doi.org/10.1016/j.clinthera.2012.03.007
Publikováno v:
Pain Practice. 11:57-69
Objective: To provide a systematic literature review of the responsiveness of patient-reported health outcomes measures for the evaluation of low back pain (LBP). Methods and Design: Searches of MEDLINE and EMBASE were performed for articles publishe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::860a8a6a1bea4bcbf08103a4a1f953c1
https://doi.org/10.1111/j.1533-2500.2010.00390.x
https://doi.org/10.1111/j.1533-2500.2010.00390.x
Publikováno v:
Journal of Medical Economics. 13:626-632
Multiple sclerosis (MS) is associated with a substantial economic burden resulting from direct medical costs associated with health and disability-related resource utilization and indirect costs relating to reduced productivity. However, reduced heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa3909e8c47c22048d81b52580ed3d16
https://doi.org/10.3111/13696998.2010.525989
https://doi.org/10.3111/13696998.2010.525989